Kodiak Sciences Inc.

Kodiak Sciences is a clinical-stage biotech developing long-acting therapies for retinal diseases — wet AMD, diabetic macular edema (DME), diabetic retinopathy. Its lead asset KSI-501 is a bispecific antibody targeting both VEGF and IL-6, aiming to compete with Eylea/Vabysmo on dosing intervals.

• The company enrolled the first patients in its global Phase 3 ALTO trial of KSI-501 in DME on Aug 10 — the specific trial that decides whether this becomes a $1B+ product or gets shelved, making everything else on the file secondary.
• Revenue is zero; consensus models $11M in 2026, $46M in 2027, then a step to $236M in 2028 — the analyst community is timing a launch, and the equity is trading on that curve pulling forward or slipping.
• Stock is +319% over 12 months, +54% year-to-date, and sits at the 80th percentile of the 52-week range — the tape has already priced meaningful Phase 3 optimism, so a good readout gets rewarded less than a bad one gets punished.
• Cash burn is running ~$40M/quarter against a $2.8B market cap — runway is comfortable at today's valuation, but any equity raise from here dilutes real percentages.

The next 12-18 months are essentially binary — a clean interim look or positive early-year data on ALTO validates the run and could re-rate the equity toward the eventual launch model; a delay or safety signal takes back a large chunk of the 4x move. What sustains the acceleration in the interim is enrollment progress and any competitor stumble in the anti-VEGF category.